This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Nathan Sadeghi-Nejad

Contributor

Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza¿s Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.

Nathan Sadeghi-Nejad
By This Author:
Page 3 of 5

Rethinking Idenix Pharma in Wake of Bristol's Hep C Blow Up

By Nathan Sadeghi-Nejad

The two Hep C drugs are similar enough chemically to warrant caution.

07:00AM 08/06/12

Gilead Sciences Firing On All Cylinders

By Nathan Sadeghi-Nejad

Gilead posted strong second-quarter earnings and is moving ahead aggressively with its new hepatitis C drugs.

07:00AM 07/30/12

The Health Care Short Sales That Never Fit

By Nathan Sadeghi-Nejad

Valuation shorts can be investment quicksand, explains TheStreet columnist Nate Sadeghi.

07:00AM 07/23/12

Eli Lilly, Verastem and the Defenders of Shareholder Value

By Nathan Sadeghi-Nejad

TheStreet contributor Nate Sadeghi calls for healthcare investors to start acting like owners.

07:07AM 07/16/12

Onyx Pharma Must Start Delivering Profits

By Nathan Sadeghi-Nejad

With a second cancer drug approval looming, Onyx can join a select group of successful and profitable biotech companies.

08:10AM 07/10/12

ObamaCare Upheld: Health Care Stock Winners and Losers

By Nathan Sadeghi-Nejad

TheStreet's Nathan Sadeghi-Nejad examines which health care stocks benefit from the Supreme Court's decision to uphold health care reform.

11:38AM 06/28/12

Arena Pharma And The Fat Lady's Song

By Nathan Sadeghi-Nejad

Advice to lorcaserin bulls: Cherish the moment but sell Arena, says TheStreet contributor Nate Sadeghi.

11:13AM 06/25/12

Alkermes Needs to Build on Drug Delivery Success

By Nathan Sadeghi-Nejad

An undervalued stock could move higher if Alkermes continues to grow through acquisitions.

07:00AM 06/18/12

A Reckoning Approaches: Supreme Court and Obama's Healthcare Reform Law

By Nathan Sadeghi-Nejad

Six possible outcomes of the Court's healthcare ruling and what it means for healthcare stocks.

07:09AM 06/11/12

Bad Romance: Glaxo's Brutal Courtship of Human Genome Sciences

By Nathan Sadeghi-Nejad

Contributor Nathan Sadeghi-Nejad offers tips to Glaxo's CEO on how to woo the stubborn HGSI into marriage.

07:45AM 06/04/12

Page 3 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs